Symbiotec Subsidiary Knovea Pharma Signs US Commercialization Deal for DCV Products

Knovea Pharmaceutical, a wholly owned subsidiary of Symbiotec Pharmalab, has entered into a strategic commercialization agreement with a leading global pharmaceutical company for its Dual Chamber Vial (DCV) based injectable products in the United States. Under the agreement, Knovea will handle development, regulatory submissions, manufacturing, and supply, while the partner will manage commercialization and distribution across the U.S. The collaboration includes milestone payments and profit-sharing. The DCV technology keeps drug and diluent separate until point of care, enhancing stability for sensitive formulations. The two products target a U.S. market estimated at approximately US$288 million. This deal is a significant step for Knovea's DCV platform and Symbiotec's complex injectables business.